Merck was dealt a blow toward the end of December after one of its cholesterol drugs, called Tredaptive, failed its outcomes study. It looks like the pharma stalwart won't seek approval from the Food and Drug Administration for this drug, but it hasn't given up on this market just yet. The company announced yesterday that the FDA will review its other cholesterol-fighter, which is a combination of the drugs ezetimibe and atorvastatin.
This therapeutic was already denied approval back in March -- but will additional data give Merck the green light this time around? What other drugs should Merck investors be watching in 2013?
Health care analyst Max Macaluso tackles these questions in the following video.
Max Macaluso, Ph.D. and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.